In this special investor guide, Tim Boreham showcases 25 pioneering Aussie health and biotech companies passing the clinical test, alongside insights from leading healthcare analysts from Morgans, Cannacord and Platinum Asset Management and Stockhead’s Nadine McGrath.

https://stockhead.com.au/investor-guides/investor-guide-health-biotech-2026-featuring-tim-boreham/